Next-generation sequencing (NGS) technologies have provided opportunities for developing personalized treatments for patients. Given the rapid advances in technology and computational complexity, there may be gaps in best practices and guidelines to support the current challenges facing Clinical Laboratory Improvement Amendments (CLIA) laboratories. Whole-genome sequencing (WGS), an NGS technology, allows for the exponential generation of human sequencing data. Bioinformatics and computational pipelines have taken advantage of these data to generate new mechanisms to aid in predicting patient treatment responses and adjusting treatments accordingly.